QDIS Blog

A blog about chemistry, drug development, science, and technology

March 7, 2007

More M&A Pharma Activity: Lilly to Acquire Hypnion

by @ 3:28 pm.  Filed under Pharma News

Eli Lilly is acquiring a small company in Mass. called Hypnion that focuses on sleeping disorders. No financial details were released.

Lilly Announces Acquisition of Hypnion

Hypnion lead candidate is HY10275 and has completed phase I and II trials earlier this year. It would likely be a non-schedule sleeping pill and is suppose to be better than those on the market.

More importantly though is the technology Lilly acquires, the SCORE-2004™ platform which is predictive software for a sleep-wake bioassay system. This could be used to make predictions of what compounds would have the best overall profile. Here is the companies quote:

Using SCORE- 2004™, the world’s only predictive sleep-wake bioassay system, we have profiled and evaluated the universe of sleep-wake pathways, screened known marketed CNS drugs which act on those targets, and optimized the sleep or wake-inducing effects of those compounds in order to produce novel, patentable New Chemical Entities (NCE’s) ready for preclinical development.

We are moving ahead with a robust program which includes multiple scaffolds and clinical candidates that have proven themselves to have distinct advantages in efficacy and safety over the market leaders in insomnia and fatigue including Lunesta™, Ambien™ and Provigil™ as well as soon to be marketed drugs including indiplon.

Interesting to note they don’t mention Rozarem (ramelteon).

If it is indeed predictive, it could be a major step forward in terms of being able to test compounds “in silico” without having to make numerous drugs and test them. It remains to be seen and I personally think these “in silico” system are overhyped and still do not take into account side effects or toxicology problems. However, it is a step forward just not as large a ne as many in the industry make it out to be, at least in my opinion.

As an aside, DTC Marketing Blog has an interesting article from back in November about Rozarem, Ambien, and Lunesta in terms of website traffic. They also have an article of Lilly acquiring Hypnion.

Technorati Tags: , , ,

Email Ed Vawter



Related Posts:
  • Eli Lilly to Acquire Icos for $2.1B Finance
  • GlaxoSmithKline To Acquire Domantis
  • AnorMED Recommends Rejecting Genzyme Offer
  • Amgen to Acquire Avidia
  • Genentech to buy Tanox for $919M in cash

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Leave a Reply

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    March 2007
    S M T W T F S
    « Feb   Apr »
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    35 queries. 0.904 seconds